← Back to Search

Immunomodulator

Povetacicept for Autoimmune Kidney Diseases (RUBY-3 Trial)

Phase 1 & 2
Recruiting
Research Sponsored by Alpine Immune Sciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study day 1 through 90 days after last dose of study drug
Awards & highlights

RUBY-3 Trial Summary

This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.

Who is the study for?
Adults with certain autoimmune kidney diseases like IgA nephropathy, membranous nephropathy, or lupus-related kidney disease can join. They must have a confirmed diagnosis through biopsy and meet specific criteria including protein levels in urine and antibody presence. Stable immunosuppression treatment is required for some conditions before starting the trial.Check my eligibility
What is being tested?
The study tests povetacicept (ALPN-303) to see if it's safe and effective for treating autoimmune kidney diseases. Participants will receive doses every four weeks for six months, with an option to continue for another six months.See study design
What are the potential side effects?
Possible side effects of povetacicept are not detailed here but may include reactions related to immune system changes since it targets autoimmune processes.

RUBY-3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study day 1 through 90 days after last dose of study drug
This trial's timeline: 3 weeks for screening, Varies for treatment, and study day 1 through 90 days after last dose of study drug for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events

RUBY-3 Trial Design

2Treatment groups
Experimental Treatment
Group I: povetacicept 80mgExperimental Treatment1 Intervention
Group II: povetacicept 240mgExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Alpine Immune Sciences, Inc.Lead Sponsor
8 Previous Clinical Trials
530 Total Patients Enrolled
Jiahua Li, M.D.Study DirectorAlpine Immune Sciences, Inc.

Media Library

Povetacicept (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT05732402 — Phase 1 & 2
Vasculitis Research Study Groups: povetacicept 80mg, povetacicept 240mg
Vasculitis Clinical Trial 2023: Povetacicept Highlights & Side Effects. Trial Name: NCT05732402 — Phase 1 & 2
Povetacicept (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05732402 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are actively participating in the research experiment?

"To meet the predetermined requirements of this trial, 42 eligible individuals must partake in the experiment. Patients hailing from Valencia, California and Orlando, Florida may join at Investigational Site (506) and Investigational Site (512), respectively."

Answered by AI

What proportion of the hospitals in this city are conducting the clinical trial?

"Presently, this research is recruiting volunteers from 6 different sites. Some of these are in Valencia, Orlando and Lawrenceville; other locations exist as well. If you choose to participate, please select the closest centre to minimize your travel requirements."

Answered by AI

To what degree could povetacicept 80mg be detrimental to one's health?

"With limited prior evidence of safety and efficacy, povetacicept 80mg was rated a 1 on our team's scale."

Answered by AI

Are there vacancies available for those wishing to participate in this trial?

"Evidenced by clinicaltrials.gov, this research is actively seeking participants with the initial post-date of March 15th 2023 and most recent update being on March 24th 2023."

Answered by AI

Who else is applying?

What site did they apply to?
Investigational Site (501)
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
2023. "An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05732402.
All > Lupus Nephritis > Iga Nephropathy
~34 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top